Share on StockTwits

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Director Rick E. Winningham sold 27,500 shares of Jazz Pharmaceuticals plc stock on the open market in a transaction that occurred on Thursday, April 17th. The shares were sold at an average price of $140.00, for a total transaction of $3,850,000.00. Following the transaction, the director now directly owns 13,587 shares of the company’s stock, valued at approximately $1,902,180. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on JAZZ shares. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc in a research note on Monday. They now have a $143.00 price target on the stock. Separately, analysts at Canaccord Genuity initiated coverage on shares of Jazz Pharmaceuticals plc in a research note on Thursday. They set a “buy” rating and a $163.00 price target on the stock. Finally, analysts at Leerink Swann cut their price target on shares of Jazz Pharmaceuticals plc from $189.00 to $170.00 in a research note on Friday, March 28th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Jazz Pharmaceuticals plc presently has an average rating of “Buy” and an average target price of $169.35.

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) traded up 1.60% on Monday, hitting $138.33. The stock had a trading volume of 557,826 shares. Jazz Pharmaceuticals plc has a 1-year low of $53.29 and a 1-year high of $176.60. The stock’s 50-day moving average is $142.0 and its 200-day moving average is $127.9. The company has a market cap of $8.033 billion and a P/E ratio of 38.79.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) last released its earnings data on Tuesday, February 25th. The company reported $1.72 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.78 by $0.06. The company had revenue of $235.80 million for the quarter, compared to the consensus estimate of $238.12 million. Analysts expect that Jazz Pharmaceuticals plc will post $8.20 EPS for the current fiscal year.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.